Finding the right balance of BRAF inhibition in melanoma

Michael A. Davies

doi:10.1158/2159-8290.CD-14-0307

Finding the right balance of BRAF inhibition in melanoma

Michael A. Davies

Melanoma Medical Oncology

Research output: Contribution to journal › Article › peer-review

3 Scopus citations

Abstract

Paradoxical activation of the mitogen-activated protein kinase pathway can cause secondary malignancies in patients treated with inhibitors of BRAF ^V600 proteins. Characterization of a patient with concurrent BRAF -mutant melanoma and NRAS -mutant leukemia treated intermittently with combined BRAF and MEK inhibition provides new insights into the potential clinical and molecular effects of this therapeutic strategy.

Original language	English (US)
Pages (from-to)	510-512
Number of pages	3
Journal	Cancer discovery
Volume	4
Issue number	5
DOIs	https://doi.org/10.1158/2159-8290.CD-14-0307
State	Published - May 2014

ASJC Scopus subject areas

Oncology

Access to Document

10.1158/2159-8290.CD-14-0307

Cite this

@article{930558f800654ac9b5e6a43be5024ce0,

title = "Finding the right balance of BRAF inhibition in melanoma",

abstract = "Paradoxical activation of the mitogen-activated protein kinase pathway can cause secondary malignancies in patients treated with inhibitors of BRAF V600 proteins. Characterization of a patient with concurrent BRAF -mutant melanoma and NRAS -mutant leukemia treated intermittently with combined BRAF and MEK inhibition provides new insights into the potential clinical and molecular effects of this therapeutic strategy.",

author = "Davies, {Michael A.}",

year = "2014",

month = may,

doi = "10.1158/2159-8290.CD-14-0307",

language = "English (US)",

volume = "4",

pages = "510--512",

journal = "Cancer discovery",

issn = "2159-8274",

publisher = "American Association for Cancer Research Inc.",

number = "5",

}

TY - JOUR

T1 - Finding the right balance of BRAF inhibition in melanoma

AU - Davies, Michael A.

PY - 2014/5

Y1 - 2014/5

N2 - Paradoxical activation of the mitogen-activated protein kinase pathway can cause secondary malignancies in patients treated with inhibitors of BRAF V600 proteins. Characterization of a patient with concurrent BRAF -mutant melanoma and NRAS -mutant leukemia treated intermittently with combined BRAF and MEK inhibition provides new insights into the potential clinical and molecular effects of this therapeutic strategy.

AB - Paradoxical activation of the mitogen-activated protein kinase pathway can cause secondary malignancies in patients treated with inhibitors of BRAF V600 proteins. Characterization of a patient with concurrent BRAF -mutant melanoma and NRAS -mutant leukemia treated intermittently with combined BRAF and MEK inhibition provides new insights into the potential clinical and molecular effects of this therapeutic strategy.

UR - http://www.scopus.com/inward/record.url?scp=84899700021&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84899700021&partnerID=8YFLogxK

U2 - 10.1158/2159-8290.CD-14-0307

DO - 10.1158/2159-8290.CD-14-0307

M3 - Article

C2 - 24795008

AN - SCOPUS:84899700021

SN - 2159-8274

VL - 4

SP - 510

EP - 512

JO - Cancer discovery

JF - Cancer discovery

IS - 5

ER -

Finding the right balance of BRAF inhibition in melanoma

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this